The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose escalation study of the protein kinase C iota inhibitor aurothiomalate for advanced non-small cell lung cancer, ovarian cancer, and pancreatic cancer.
Aaron Scott Mansfield
No relevant relationships to disclose
Alan P. Fields
No relevant relationships to disclose
Aminah Jatoi
No relevant relationships to disclose
Yingwei Qi
No relevant relationships to disclose
Alex A. Adjei
No relevant relationships to disclose
Charles Erlichman
No relevant relationships to disclose
Julian R. Molina
No relevant relationships to disclose